secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2022-03-21T23:59:59+00:00
Accession:  0000950170-22-004229
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns' TERN-201 Phase 1b AVIATION trial meets safety; no efficacy in NASH
-------------------------------------------------------------------------

- Part 1 of Phase 1b AVIATION trial of TERN-201 10 mg met primary safety endpoint; well-tolerated with no SAEs.
- No meaningful changes in exploratory NASH biomarkers (cT1, ALT, AST, GGT, CK-18) vs placebo.
- Near complete (>98%) VAP-1 inhibition achieved but no efficacy signals.
- Part 2 (20 mg) ongoing; top-line results expected H2 2022.
- Cash runway into 2024; pipeline includes TERN-501 Phase 2a in H1 2022 and TERN-601 Phase 1 in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017022004229/0000950170-22-004229-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017022004229/tern-20220321.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-004229

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer